Peptide Profile

DSIP

Delta Sleep-Inducing Peptide

Research Only10 sourcesShop DSIP

Overview

Composition

Naturally occurring nonapeptide (nine-amino-acid chain) originally identified for its potential to influence sleep patterns

Mechanism of Action

Enhances delta-wave (slow-wave) sleep associated with deep, restorative rest, while modulating stress responses, pain perception, and certain endocrine functions

Primary Effects

Studied for effects on slow-wave sleep, sleep latency, circadian disruption, stress response, and pain signaling, with inconsistent and older human evidence

Discovery & Background

First isolated in 1977 by a Swiss research team led by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced sleep

Discovery stemmed from efforts to identify endogenous factors that promote delta-wave activity in the brain; subsequent research expanded its scope beyond sleep to include stress adaptation, pain modulation, and potential neuroprotective effects

Lacks widespread approval for clinical use and is primarily explored as a research compound; remains investigational with limited large-scale trials

Research Overview

Most investigations involve animal models and limited human trials, primarily from the 1980s and 1990s

01
Older studies reported changes in sleep architecture in some insomnia contexts
02
Stress-related symptom and resilience claims remain preliminary
03
Pain studies include chronic headache, fibromyalgia, and neuropathic-pain contexts but are not definitive
04
Substance-withdrawal research is limited and should not be generalized
05
Cortisol and relaxation claims require careful interpretation because replication is inconsistent
06
Human data remain limited and inconsistent, with some trials failing to replicate clear effects

Not approved for clinical use; remains primarily a research compound with limited and inconsistent human data

Safety Considerations

Monitoring

Sleep quality and architecture
Mood and stress levels
Pain markers
Circadian rhythm stability
Overall well-being

Side Effects

Common

Generally well-tolerated in reports
Occasional mild dizziness
Mild nausea (rare)

Local

No well-characterized adverse-event profile has been established in modern trials

Contraindications

Limited human clinical evidence
Not approved by regulatory agencies for therapeutic use
Individual responses vary; professional oversight essential

Educational Notice

DSIP remains a research peptide with older, mixed human literature for sleep, stress, and pain endpoints. It is not approved by major regulatory agencies for therapeutic use, and clinical decisions require qualified medical oversight.

References